
    
      This is a global, multicenter, open-label, single-arm Phase 2 study to evaluate the efficacy
      and safety of moxetumomab pasudotox monotherapy in pediatric participants with relapsed or
      refractory B-cell ALL or B-cell lymphoblastic lymphoma. Participants will be enrolled at
      sites in North America, Europe, and Australia. This is an approximate 35 month study.
    
  